Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients

  title={Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients},
  author={M. Besser and R. Shapira-Frommer and A. Treves and D. Zippel and O. Itzhaki and Liat Hershkovitz and Daphna Levy and A. Kubi and E. Hovav and Natalia Chermoshniuk and B. Shalmon and I. Hardan and R. Catane and G. Markel and S. Apter and A. Ben-nun and I. Kuchuk and A. Shimoni and A. Nagler and J. Schachter},
  journal={Clinical Cancer Research},
  pages={2646 - 2655}
Purpose: Adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TIL) has shown promising results in metastatic melanoma patients. Although objective response rates of over 50% have been reported, disadvantages of this approach are the labor-intensive TIL production and a very high drop-out rate of enrolled patients, limiting its widespread applicability. Previous studies showed a clear correlation between short TIL culture periods and clinical response. Therefore, we used a new… Expand

Paper Mentions

Interventional Clinical Trial
This study is to investigate safety and feasibility of a combination therapy of a tumor infiltrating lymphocytes (TIL) transfer with anti-programmed cell death protein (PD)-1… Expand
ConditionsAdvanced Melanoma
Interventional Clinical Trial
Metastatic melanoma is an aggressive and highly malignant cancer. The five-year survival rate of patients with metastatic disease is less than 5% with a median survival of only 6-10… Expand
ConditionsMetastatic Melanoma
Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients
A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma
Adoptive T-cell transfer in melanoma.
Focus on Adoptive T Cell Transfer Trials in Melanoma


Adoptive cell therapy for the treatment of patients with metastatic melanoma.
In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.
Minimally Cultured Tumor-infiltrating Lymphocytes Display Optimal Characteristics for Adoptive Cell Therapy
Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response.
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
Adoptive cell transfer therapy.